inclusion criteria: 1. availability of the informed consent form of thepatient information leaflet (pil) signed and dated bypatient. 2. men and women aged 18 to 80 years inclusive at thetime of signing the informed consent form in pil. 3. confirmed case of covid-19 at the time ofscreening based on sars-cov-2 rna test usingnucleic acid amplification (naa) method. it isacceptable to include a patient with a presumptivecovid-19 diagnosis prior to receiving the results ofsars-cov-2 rna test made at the screening stage. 4. hospital admission due to covid-19. 5. moderate severity infection with sars-cov-2: clinical signs (the presence of at least 2 of the following criteria): * body temperature \> 38 °c; * rr \> 22/min; * ct pattern typical of a viral lesion * shortness of breath on exertion; * spo2 \< 95%; * serum crp \> 10 mg/l. 6. lesion volume is minimal or moderate; ct 1-2. 7. patient's consent to use reliable contraceptive methods through out the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexualabstinence, use of condom in combination withspermicide. women incapable of childbearing may also participate inthe study (with past history of: hysterectomy, tubal ligation,infertility, menopause for more than 2 years), as well asmen with infertility or a history of vasectomy

inclusion criteria: 1. availability of the informed consent form of thepatient information leaflet (pil) signed and dated bypatient. 2. men and women aged 18 to 80 years inclusive at thetime of signing the informed consent form in pil. 3. confirmed case of covid-19 at the time ofscreening based on sars-cov-2 rna test usingnucleic acid amplification (naa) method. it isacceptable to include a patient with a presumptivecovid-19 diagnosis prior to receiving the results ofsars-cov-2 rna test made at the screening stage. 4. hospital admission due to covid-19. 5. moderate severity infection with sars-cov-2: clinical signs (the presence of at least 2 of the following criteria): * body temperature \> 38 °c; * rr \> 22/min; * ct pattern typical of a viral lesion * shortness of breath on exertion; * spo2 \< 95%; * serum crp \> 10 mg/l. 6. lesion volume is minimal or moderate; ct 1-2. 7. patient's consent to use reliable contraceptive methods through out the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexualabstinence, use of condom in combination withspermicide. women incapable of childbearing may also participate inthe study (with past history of: hysterectomy, tubal ligation,infertility, menopause for more than 2 years), as well asmen with infertility or a history of vasectomy

inclusion criteria: availability of the informed consent form of thepatient information leaflet (pil) signed and dated bypatient. men and women aged 18 to 80 years inclusive at thetime of signing the informed consent form in pil. confirmed case of covid-19 at the time ofscreening based on sars-cov-2 rna test usingnucleic acid amplification (naa) method. it isacceptable to include a patient with a presumptivecovid-19 diagnosis prior to receiving the results ofsars-cov-2 rna test made at the screening stage. hospital admission due to covid-19. moderate severity infection with sars-cov-2: clinical signs (the presence of at least 2 of the following criteria): body temperature > 38 °c; rr > 22/min; ct pattern typical of a viral lesion shortness of breath on exertion; spo2 < 95%; serum crp > 10 mg/l. lesion volume is minimal or moderate; ct 1-2. patient's consent to use reliable contraceptive methods through out the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexualabstinence, use of condom in combination withspermicide. women incapable of childbearing may also participate inthe study (with past history of: hysterectomy, tubal ligation,infertility, menopause for more than 2 years), as well asmen with infertility or a history of vasectomy

inclusion criteria: availability of the informed consent form of thepatient information leaflet (pil) signed and dated bypatient. men and women aged 18 to 80 years inclusive at thetime of signing the informed consent form in pil. confirmed case of covid-19 at the time ofscreening based on sars-cov-2 rna test usingnucleic acid amplification (naa) method. it isacceptable to include a patient with a presumptivecovid-19 diagnosis prior to receiving the results ofsars-cov-2 rna test made at the screening stage. hospital admission due to covid-19. moderate severity infection with sars-cov-2: clinical signs (the presence of at least 2 of the following criteria): body temperature > 38 °c; rr > 22/min; ct pattern typical of a viral lesion shortness of breath on exertion; spo2 < 95%; serum crp > 10 mg/l. lesion volume is minimal or moderate; ct 1-2. patient's consent to use reliable contraceptive methods through out the study and within 1 month for women and 3 months for men after its completion. reliable means of contraception are: sexualabstinence, use of condom in combination withspermicide. women incapable of childbearing may also participate inthe study (with past history of: hysterectomy, tubal ligation,infertility, menopause for more than 2 years), as well asmen with infertility or a history of vasectomy